ZIM
ADMA icon

Zacks Investment Management’s ADMA Biologics ADMA Stock Holding History

Zacks Investment Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-118,702
Closed -$1.07M – 726
2026
Q1 		$1.07M Buy
+118,702
New +$1.87M 0.01% 402
2025
Q3 		– Sell
-205,578
Closed -$3.74M – 740
2025
Q2 		$3.74M Sell
205,578
-48,214
-19% -$983K 0.03% 256
2025
Q1 		$5.04M Sell
253,792
-870
-0.3% -$15K 0.05% 215
2024
Q4 		$4.37M Sell
254,662
-33,347
-12% -$627K 0.04% 237
2024
Q3 		$5.76M Buy
+288,009
New +$4.48M 0.05% 199
2024
Q2 		– Sell
-282,846
Closed -$1.87M – 614
2024
Q1 		$1.87M Buy
+282,846
New +$1.55M 0.02% 323

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Zacks Investment Management's ADMA Position: Q2 2026 in Review

Zacks Investment Management sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 118,702 shares — an estimated $1.07M sold.

Zacks Investment Management first reported a position in ADMA in Q1 2024 and held it in 6 quarters. The position peaked at $5.76M in Q3 2024. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Zacks Investment Management reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Zacks Investment Management sold 118,702 ADMA Biologics shares in Q2 2026, an estimated $1.07M.
  • Zacks Investment Management first reported a position in ADMA Biologics in Q1 2024 and held it in 6 quarters.
  • Zacks Investment Management's ADMA Biologics position peaked at $5.76M in Q3 2024.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Zacks Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.